Search 

Astrocyte Pharmaceuticals is a preclinical CNS drug development company advancing breakthrough therapeutic agents for treating brain injury patients. Astrocyte is developing the proprietary small molecule pharmaceutical agent AST-004 for acute administration to patients who have suffered a stroke, TBI, or concussion. This product would be administered by intravenous injection by emergency responders or a medical professional within 24 hours of injury to limit neuronal damage and cell death. Our approach at Astrocyte Pharmaceuticals differs significantly from historical neuroprotective attempts as we focus on a non-neuronal cell type, the astrocyte, which is the most common cell type in the human brain and has only recently received broader attention as an important cellular target for therapeutic research. The company recently demonstrated AST-004's significant efficacy in an NHP stroke study that mirrors the planned Phase 2 clinical study, and large safety margins in GLP toxicology studies. The company completed its Series A financing in Q4 2020.

A private pharmaceutical company,headquartered in Beijing,focus on the research, development,manufacture and marketing of drug products for the treatment of organ fibrosis diseases and other related diseases.

EpicentRx is an immuno-oncology company whose focus is to identify and develop less toxic and more effective immunotherapy-based anti-cancer treatments that are active not only as single agents, but that also sensitize tumors to the cytotoxic effects of chemotherapy, radiation and immune checkpoint blockade. EpicentRx's lead program is among a portfolio of novel dinitroazetidine-based drugs that downregulate CD47 – SIRPα to alter the tumor microenvironment and optimize immune responses as well as normalize the tumor vasculature for better drug and oxygen delivery, and has been tested in several clinical trials including an ongoing Phase 3 study in SCLC. The company is also advancing multiple programs through its smart virus AdAPT platform, including three anti-SARS-CoV-2 vaccines, a TGF-beta "trap" starting Phase 1, and various personalized cancer vaccines that have shown to be effective in both chemotherapy and immune resistant tumors. For more information regarding EpicentRx, go to: http://www.epicentrx.com.

GIG, one of the leading healthcare investment institute, was founded in Shenzhen in 2001. AUM is RMB ￥20b. It has invested in 80+ healthcare companies. 22 went IPO. GIG has 90+ staff in team with operating offices in Shenzhen, Shanghai, Beijing, Nanjing and Hongkong.

Jemincare is a leading pharmaceutical group in China with $5.2B revenue in 2019. JeminCare is dedicated to providing novel healthcare solutions with Rx and OTC drugs with strategic fields in renal disease, oncology, cardiovascular, anti-infection, respiratory, and analgesic. We have a well-established marketing and sales network in China with a team of more than 5000 sales reps.

Located in Shanghai, Jemincare R&D center has 400+ experienced scientists and more than 30 novel prescription drugs in the pipeline.